Els Wauters

Erasmus MC — Netherlands

Medicine · Health Sciences

39h-index9.1kcitations155works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(32), COVID-19 Clinical Research Studies(23), Lung Cancer Treatments and Mutations(22), Cancer Genomics and Diagnostics(14), SARS-CoV-2 and COVID-19 Research(13)

Publications145 total

Drug-Induced Interstitial Lung Disease in Lung Cancer Patients
Respiration·2025Open Access
Nanopore long-read sequencing for the critically ill facilitates ultrarapid diagnostics and urgent clinical decision making
European Journal of Human Genetics·2025· 3 citedOpen Access
Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer
ESMO Open·2025Open Access
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor Pneumonitis
American Journal of Respiratory Cell and Molecular Biology·2025· 2 cited
Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment
Cell Reports Medicine·2025· 2 citedOpen Access
1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01
Annals of Oncology·2025· 2 citedOpen Access
Late Recurrence of Mucinous Adenocarcinoma after Lung Transplantation: A Case Report and Literature Review
Case Reports in Oncology·2025Open Access
Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An ESTRO clinical practice guideline
Radiotherapy and Oncology·2025· 17 citedOpen Access
OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%
Journal of Thoracic Oncology·2024· 14 citedOpen Access
Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC
Cancer Research·2024· 3 cited
Abstract 1182: PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer
Cancer Research·2024
113P A propensity-based analysis of SBRT and VATS for early-stage lung cancer: A guide to data-driven support and decision-making in a multidisciplinary tumour board
ESMO Open·2024Open Access
Lower respiratory tract single-cell RNA sequencing and neutrophil extracellular trap profiling of COVID-19-associated pulmonary aspergillosis: a single centre, retrospective, observational study
The Lancet Microbe·2024· 25 citedOpen Access
Pneumonitis after Chemoradiotherapy And/Or Immunotherapy for Stage Iii and IV Non-Small Cell Lung Cancer is Characterized by Specific Radiologic and Quantitative Ct Features
SSRN Electronic Journal·2024Open Access
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
Annals of Oncology·2023· 9 citedOpen Access
Proteolytic inactivation of CXCL12 in the lungs and circulation of COVID-19 patients
Cellular and Molecular Life Sciences·2023· 9 citedOpen Access
Trial watch: chemotherapy-induced immunogenic cell death in oncology
OncoImmunology·2023· 74 citedOpen Access
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
Journal of Clinical Oncology·2023· 17 citedOpen Access
Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients
International review of cell and molecular biology·2023· 2 citedOpen Access
Visualising SARS-CoV-2 infection of the lung in deceased COVID-19 patients
EBioMedicine·2023· 12 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Diether Lambrechts(24), Joost Wauters(16), Bram Boeckx(14), Pierre Van Mol(14), Birgit Weynand(10), Yannick Van Herck(10), Lore Vanderbeke(10), Greet Hermans(9), Sander Jansen(8), Philippe Meersseman(8), Robin Vos(8), Johan Neyts(8), Bernard Thienpont(7), Christophe Dooms(7), Jan Gunst(7), Dries Testelmans(7), Paul Proost(7), Johan Vansteenkiste(6), Sabine Tejpar(6), Johan Vansteenkiste(6)